143 related articles for article (PubMed ID: 10760759)
1. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma.
Chu KU; Ravindranath MH; Gonzales A; Nishimoto K; Tam WY; Soh D; Bilchik A; Katopodis N; Morton DL
Cancer; 2000 Apr; 88(8):1828-36. PubMed ID: 10760759
[TBL] [Abstract][Full Text] [Related]
2. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
Ravindranath NM; Nishimoto K; Chu K; Shuler C
Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630
[TBL] [Abstract][Full Text] [Related]
3. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications.
Perez CA; Ravindranath MH; Soh D; Gonzales A; Ye W; Morton DL
Cancer J; 2002; 8(5):384-94. PubMed ID: 12416896
[TBL] [Abstract][Full Text] [Related]
4. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM.
Ravindranath MH; Wood TF; Soh D; Gonzales A; Muthugounder S; Perez C; Morton DL; Bilchik AJ
Cryobiology; 2002 Aug; 45(1):10-21. PubMed ID: 12445546
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against gangliosides in patients with SLE and neurological manifestations.
Martinez X; Tintoré M; Montalbán J; Ordi J; Vilardell M; Codina A
Lupus; 1992 Oct; 1(5):299-302. PubMed ID: 1303222
[TBL] [Abstract][Full Text] [Related]
6. Significance of endogenous augmentation of antiganglioside IgM in cancer patients: potential tool for early detection and management of cancer therapy.
Ravindranath MH; Muthugounder S; Hannah MR; Morton DL
Ann N Y Acad Sci; 2007 Jun; 1107():212-22. PubMed ID: 17804549
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic gangliosides in human ovarian carcinoma.
Ravindranath MH; Muthugounder S; Presser N; Selvan SR; Santin AD; Bellone S; Saravanan TS; Morton DL
Biochem Biophys Res Commun; 2007 Feb; 353(2):251-8. PubMed ID: 17188646
[TBL] [Abstract][Full Text] [Related]
8. Potential target antigens for immunotherapy in human pancreatic cancer.
Schmitz-Winnenthal FH; Galindo-Escobedo LV; Rimoldi D; Geng W; Romero P; Koch M; Weitz J; Krempien R; Niethammer AG; Beckhove P; Buchler MW; Z'graggen K
Cancer Lett; 2007 Jul; 252(2):290-8. PubMed ID: 17320278
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism involved in increased expression of sialyl Lewis antigens in ductal carcinoma of the pancreas.
Nakamori S; Nishihara S; Ikehara Y; Nagano H; Dono K; Sakon M; Narimatsu H; Monden M
J Exp Clin Cancer Res; 1999 Sep; 18(3):425-32. PubMed ID: 10606190
[TBL] [Abstract][Full Text] [Related]
10. [Antiganglioside autoantibody profiles in Guillain-Barré syndrome].
Caudie C; Vial C; Bancel J; Petiot P; Antoine JC; Gonnaud PM
Ann Biol Clin (Paris); 2002; 60(5):589-97. PubMed ID: 12368145
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival.
Quiros RM; Rao G; Plate J; Harris JE; Brunn GJ; Platt JL; Gattuso P; Prinz RA; Xu X
Cancer; 2006 Feb; 106(3):532-40. PubMed ID: 16388520
[TBL] [Abstract][Full Text] [Related]
12. Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma.
Ravindranath MH; Amiri AA; Bauer PM; Kelley MC; Essner R; Morton DL
Cancer; 1997 May; 79(9):1686-97. PubMed ID: 9128983
[TBL] [Abstract][Full Text] [Related]
13. Human antiganglioside autoantibodies: validation of ELISA.
Ravindranath MH; Muthugounder S; Saravanan TS; Presser N; Morton DL
Ann N Y Acad Sci; 2005 Jun; 1050():229-42. PubMed ID: 16014538
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
[TBL] [Abstract][Full Text] [Related]
15. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
16. Natural immune response involving anti-endothelial cell antibodies in normal and lupus pregnancy.
Mendonca LL; Khamashta MA; Cuadrado MJ; Bertolaccini ML; Hughes GR
Arthritis Rheum; 2000 Jul; 43(7):1511-5. PubMed ID: 10902753
[TBL] [Abstract][Full Text] [Related]
17. Systemic and local immunosuppression in pancreatic cancer patients.
von Bernstorff W; Voss M; Freichel S; Schmid A; Vogel I; Jöhnk C; Henne-Bruns D; Kremer B; Kalthoff H
Clin Cancer Res; 2001 Mar; 7(3 Suppl):925s-932s. PubMed ID: 11300493
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of sialyl-Lewis A correlates with poor survival in upper urinary tract urothelial cancer patients.
Saito K; Fujii Y; Kawakami S; Hayashi T; Arisawa C; Koga F; Kageyama Y; Kihara K
Anticancer Res; 2003; 23(4):3441-6. PubMed ID: 12926087
[TBL] [Abstract][Full Text] [Related]
19. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
20. Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma.
Ozaki Y; Kontani K; Hanaoka J; Chano T; Teramoto K; Tezuka N; Sawai S; Fujino S; Yoshiki T; Okabe H; Ohkubo I
Cancer; 2002 Nov; 95(9):1954-62. PubMed ID: 12404290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
